Positive Remyelination Trial Results: Late Breaking at ECTRIMS 2025
Update: 2025-10-02
Description
At the late breaking abstracts session at ECTRIMS 2025 in Barcelona, the CCMR-Two trial revealed promising results for myelin repair in MS using the diabetes drug metformin and the antihistamine clemastine. Straight from his presentation, trial lead Dr. Nick Cunniffe of the University of Cambridge sat down with host Brett Drummond of MStranslate to discuss the full results of CCMR-Two, our current understanding of myelin repair biology, and the next steps for remyelination clinical trials and potential future MS therapies.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
